影响局限期或局部晚期前列腺癌患者治疗决策与决策后悔的因素:一项系统文献综述
该系统文献综述检索三个在线数据库、部分会议论文集和灰色文献(2022年9月),纳入75篇出版物(68项研究)报告治疗决策,49篇报告决策后悔。影响治疗决策的关键因素为医生推荐、年龄、种族和治疗特征;影响决策后悔的关键因素为治疗毒性(性/泌尿/肠道功能障碍)、患者在决策中的角色和治疗类型。作者认为需要患者、照护者与医生之间共享、共识性的决策方法。
要点
- 影响治疗决策的关键因素为医生推荐、年龄、种族和治疗特征/毒性。
- 决策后悔比例随治疗类型而异:主动监测7-43%、根治性前列腺切除术12-57%、放疗1-49%、雄激素剥夺治疗28-49%、联合治疗21-47%。
- 影响决策后悔的关键因素为治疗毒性(性/泌尿/肠道功能障碍)、患者在决策中的角色和治疗类型。
核心结论
- 影响治疗决策的关键因素为医生推荐、年龄、种族和治疗特征;影响决策后悔的关键因素为治疗毒性和治疗决策方法。
- 为帮助患者应对影响治疗决策的因素并限制决策后悔,需要患者、照护者与医生之间采用共享、共识性的治疗决策方法。
研究设计与样本
- 两项系统文献综述,检索三个在线数据库、部分会议论文集和灰色文献(2022年9月),遵循PRISMA指南。
- 优先纳入2012年以来、≥100例患者、期刊论文且有定量数据的局限期/局部晚期前列腺癌治疗决策与决策后悔相关出版物。
- 共75篇出版物(68项研究)报告治疗决策,49篇出版物报告决策后悔。
主要发现
- 34篇出版物报告患者参与治疗决策,总体而言患者偏好主动/共享角色。
- 39个影响治疗决策的因素中,年龄、种族、外部因素(医生推荐最常见)和治疗特征/毒性为关键因素。
- 决策后悔比例随治疗类型而异:主动监测7-43%、根治性前列腺切除术12-57%、放疗1-49%、雄激素剥夺治疗28-49%、联合治疗21-47%。
- 42个显著决策后悔因素中,治疗毒性(性/泌尿/肠道功能障碍)、患者在治疗决策中的角色和治疗类型为关键因素。
关键数值与推荐
- 影响因素的判定标准为p<0.05;治疗决策因素还包括被描述为「决策驱动因素」「相关」「有影响」或「显著」者。
- 关键因素由研究数量、证据一致性和研究质量确定。
临床怎么用
- 作者认为,为帮助患者应对影响治疗决策的因素并限制决策后悔,需要患者、照护者与医生之间采用共享、共识性的治疗决策方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Treatment decision-making (TDM) for patients with localized (LPC) or locally advanced (LAPC) prostate cancer is complex, and post-treatment decision regret (DR) is common. The factors driving TDM or predicting DR remain understudied. OBJECTIVE: Two systematic literature reviews were conducted to explore the factors associated with TDM and DR. EVIDENCE ACQUISITION: Three online databases, select congress proceedings, and gray literature were searched (September 2022). Publications on TDM and DR in LPC/LAPC were prioritized based on the following: 2012 onward, ≥100 patients, journal article, and quantitative data. The Preferred Reporting Items Reviews and Meta-analyses guidelines were followed. Influential factors were those with p < 0.05; for TDM, factors described as "a decision driver", "associated", "influential", or "significant" were also included. The key factors were determined by number of studies, consistency of evidence, and study quality. EVIDENCE SYNTHESIS: Seventy-five publications (68 studies) reported TDM. Patient participation in TDM was reported in 34 publications; overall, patients preferred an active/shared role. Of 39 influential TDM factors, age, ethnicity, external factors (physician recommendation most common), and treatment characteristics/toxicity were key. Forty-nine publications reported DR. The proportion of patients experiencing DR varied by treatment type: 7-43% (active surveillance), 12-57% (radical prostatectomy), 1-49% (radiotherapy), 28-49% (androgen-deprivation therapy), and 21-47% (combination therapy). Of 42 significant DR factors, treatment toxicity (sexual/urinary/bowel dysfunction), patient role in TDM, and treatment type were key. CONCLUSIONS: The key factors impacting TDM were physician recommendation, age, ethnicity, and treatment characteristics. Treatment toxicity and TDM approach were the key factors influencing DR. To help patients navigate factors influencing TDM and to limit DR, a shared, consensual TDM approach between patients, caregivers, and physicians is needed. PATIENT SUMMARY: We looked at factors influencing treatment decision-making (TDM) and decision regret (DR) in patients with localized or locally advanced prostate cancer. The key factors influencing TDM were doctor's recommendation, patient age/ethnicity, and treatment side effects. A shared, consensual TDM approach between patients and doctors was found to limit DR.
引用
- Gartrell BA, Phalguni A, Bajko P, et al. Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review. Eur Urol Oncol. 2024. PMID: 38744587. doi:10.1016/j.euo.2024.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。